Drug Discovery and Development Market in Asia - Partnerships Between MNCs and Asian Academic Institutions and Healthcare Research Organizations are Driving R&D Innovation

Drug Discovery and Development Market in Asia - Partnerships Between MNCs and Asian Academic Institutions and Healthcare Research Organizations are Driving R&D Innovation


November 9, 2012
106 Pages - SKU: XGBR4910240
License type:
Online Download      US $3,500.00
Site License      US $7,000.00
Global Site License      US $10,500.00
Countries covered: Asia



Drug Discovery and Development Market in Asia - Partnerships Between MNCs and Asian Academic Institutions and Healthcare Research Organizations are Driving R&D Innovation

Summary

GBI Research, a leading business intelligence provider, has released its latest research, “Drug Discovery and Development Market in Asia - Partnerships Between MNCs and Asian Academic Institutions and Healthcare Research Organizations are Driving R&D Innovation”. The report provides key data, information and analysis of the major trends and issues affecting the drug discovery and development market in seven major countries in Asia, namely China, India, Russia, Japan, Singapore, Taiwan and South Korea. The report provides a comprehensive insight into market segmentation, covering drug discovery and development market sizes, the strategic context for deciding a location in Asia to conduct clinical research, strategies adopted by global pharmaceutical companies in outsourcing R&D processes to Asian countries, and the regulatory landscapes there. The report provides a detailed analysis of the regulatory authorities, clinical trial approval processes and recent regulatory changes in the clinical trial environment. The report analyzes the competitive landscape of the market, profiling key Contract Research Organizations (CRO) market players, along with a brief description of the business, major services and major M&A and partnership deals. The report also provides detailed analysis of major partnership and M&A deals that have taken place in the Asian drug discovery and development market along with segmentation by year, deal type, geography and phase of development.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

GBI Research finds that the total drug discovery and development market size in the top seven Asian countries was estimated at $5.3 billion in 2011 and is forecast to reach $17.3 billion by the end of 2018. Revenue growth has been surpassed by investments in pharmaceutical R&D that have not increased the output of new medicines. Research-based pharmaceutical companies outsource R&D processes to CROs which offer integrated services across the life-sciences R&D value chain. Globalization in the clinical trial industry has led to an increased number of trials being conducted in emerging markets.

The CRO industry has been witnessing strategic deals between large global CROs with broad therapeutic and functional expertise, and subcontracting local CROs. This will enable global CROs to increase their market access capabilities, thereby further increasing the extent of their outsourcing activities. The entry of new participants into the biopharmaceutical sector will augment the drug discovery and development market in Asian countries. For example, Samsung Electronics entered into the biopharmaceutical market in April 2011 through the formation of Samsung Biologics, a joint venture company between Samsung Electronics and Quintiles. In December, 2011 Samsung entered into another agreement with Biogen Idec to set up a joint venture for the development, manufacture and marketing of biosimilars.

Scope
  • Detailed overview of global trends in pharmaceutical R&D, followed by market segmentation of the Asian drug discovery and development market in seven major countries, which are China, India, Japan, South Korea, Taiwan, Russia and Singapore.
  • Annualized market data from 2007 and forecasts to 2018.
  • Strategies adopted by global pharmaceutical companies in outsourcing R&D processes to Asian countries, along with the strategic context for deciding locations in Asia for conducting clinical research.
  • Competitive landscape analysis, with profiles of the leading companies such as Quintiles Transnational Corp, Pharmaceutical Product Development Inc., Covance Inc., Parexel International Corporation and Charles River Laboratories International, Inc.
  • Analysis of partnership and M&A deals from 2004 to June 2012 along with segmentation by year and geography, deal type, and phases of development.
Reasons to buy
  • Align your product portfolio to markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the key areas for high growth and opportunities.
  • Understand the factors shaping the Asian drug discovery and development market.
  • Identify the key players best positioned to take the advantage of the opportunities in the Asian drug discovery and development market.
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.


Additional Information

Drug Research in Asia Goes Native

High recruitment rates and a robust regulatory framework strongly favour the Asian clinical research industry - and now pharma giants are going beyond simple outsourcing to study the region’s own health problems, states a new report by healthcare experts GBI Research.

The new report* explains that Asia offers a favourable environment for pharmaceutical progress, thanks to low costs, a large potential trial population and regulatory support. For example, oncology studies have now started to investigate the Asian phenotype, in order to learn even more about the nature of cancer.

During this year, over 12% of global clinical trials were carried out in the seven major markets of Asia, trailing behind the US share of 48.5%, and Europe’s 26.5%. Many Western biopharmaceutical companies are beginning to take advantage of emerging countries, where Asian regulatory agencies are streamlining the clinical trial process to meet global demand for cheap clinical research, but the vast opportunity in Asia has not yet been fully leveraged by the developed markets.

The cost of conducting clinical trials in Asian countries is 35%–45% lower than the cost of conducting similar trials in the US, as they are able to recruit a large number of patients from urban centres easily and at a low cost. The regulatory systems in Asia also offer a favourable environment, as the adoption of Good Clinical Practice (GCP) guidelines and the establishment of Institutional Review Boards (IRBs) is helping the region to quickly evolve and integrate with international standards.

Oncology is a key therapeutic area where the study of Asian patients can help pharma companies. The regional population has a high prevalence of liver cancer (due to infections of hepatitis B and C), stomach cancer, and head and neck cancer, so companies are focusing on discovering and developing medicines specifically to treat Asian diseases. This has developed from an earlier trend of finding use of an approved drug developed for a non-Asian phenotype. The Asia Oncology Strategic Alliance, launched by AstraZeneca in 2007, highlights the interest pharmaceutical companies have in the discovery and development of medicines specifically to treat Asian diseases. The aim of the alliance was to evaluate novel treatments for stomach and liver cancers in China, Japan, South Korea and Singapore, as the governments of these countries prioritized cancer therapy.

GBI Research estimates that the total market size of China, India, Russia, Japan, Singapore, Taiwan and South Korea’s drug discovery and development markets reached an impressive $5.3 billion in 2011, following growth at a Compound Annual Growth Rate (CAGR) of 21.9% from 2007. The market is expected to reach $17.3 billion in 2018, at a CAGR of 18.4%.

*Drug Discovery and Development Market in Asia - Partnerships Between MNCs and Asian Academic Institutions and Healthcare Research Organizations are Driving R&D Innovation

This report provides key data, information and analysis of the major trends and issues affecting the drug discovery and development market in seven major countries in Asia, namely China, India, Russia, Japan, Singapore, Taiwan and South Korea. It provides a comprehensive insight into market segmentation, covering drug discovery and development market sizes, the strategic context for deciding a location in Asia to conduct clinical research, strategies adopted by global pharmaceutical companies in outsourcing R&D processes to Asian countries, and the regulatory landscapes there. The report also provides a detailed analysis of the regulatory authorities, clinical trial approval processes and recent regulatory changes in the clinical trial environment.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Companies Mentioned

Siemens Healthcare
Fresenius Medical Care AG & Co. KGaA
GE Healthcare
F. Hoffmann-La Roche Ltd.
Philips Healthcare
Essilor International
DePuy, Inc.
Medtronic, Inc.
Boston Scientific Corporation
Mindray Medical International Limited
Shandong Weigao Group Medical Polymer
WuHan VSD Medical Science & Technology Co. Ltd.
Neusoft Medical Systems Co., Ltd.

More Drug Discovery reports by GBI Research

Epilepsy Therapeutics in Major Developed Markets to 2019 - New AEDs with Novel Mechanisms of Action Signal a Shift in Treatment Patterns by GBI Research
Epilepsy Therapeutics in Major Developed Markets to 2019 - New AEDs with Novel Mechanisms of Action Signal a Shift in Treatment PatternsSummaryGBI Research has released ...
Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability by GBI Research
Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and TolerabilitySummaryGBI Research, the leading ...
Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive towards Personalized Treatment and Market Growth by GBI Research
Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive towards Personalized Treatment and Market GrowthSummaryGBI Research, a leading business intelligence ...
Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth by GBI Research
Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive GrowthSummaryGBI Research has released its ...
See all reports like this >>

More Asia Drug Discovery reports

Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability by GBI Research
Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and TolerabilitySummaryGBI Research, the leading ...
China Orthobiologics Market Outlook to 2020 by GlobalData
China Orthobiologics Market Outlook to 2020SummaryGlobalData’s new report, China Orthobiologics Market Outlook to 2020, provides key market data on the China Orthobiologics market. The report ...
PharmaPoint: Schizophrenia - Japan Drug Forecast and Market Analysis to 2022 by GlobalData
PharmaPoint: Schizophrenia - Japan Drug Forecast and Market Analysis to 2022SummarySchizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core ...
PharmaPoint: Crohn’s Disease - India Drug Forecast and Market Analysis to 2022 by GlobalData
PharmaPoint: Crohn’s Disease - India Drug Forecast and Market Analysis to 2022SummaryThe Crohn’s disease (CD) market is currently very dynamic, with novel biologic therapies on ...
See all reports like this >>

More Asia reports

Eyewear in Hong Kong, China by Euromonitor International
Eyewear in Hong Kong, ChinaThe growth rate has been slowing down since 2011 in the eyewear market. The economy in Hong Kong and China saw ...
Oral Hygiene – Malaysia – a snapshot (2013) by Mintel - Snapshots
Oral Hygiene in Malaysia by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2013. This market covers ...
Country Risk Service Indonesia July 2013 by The Economist Intelligence Unit
Country Risk Service is a comprehensive two-year forecasting service that monitors risks in 100 key emerging markets. It is designed for commercial bankers, institutional investors ...
BC - West Sulawesi Cocoa Processing Plant - Indonesia - Construction Project Profile by World Market Intelligence
BC - West Sulawesi Cocoa Processing Plant - Indonesia - Construction Project Profile-SynopsisThe BC - West Sulawesi Cocoa Processing Plant - Indonesia - Construction Project ...
See all reports like this >>